在骨髓纤维化中使用新的Janus-kinase (JAK) 抑制剂
Yildiz Ipek1, Berkay Kilic2, Ulgar Boran Gunay2
1Division of Hematology, Department of Internal Medicine, Kartal Dr. Lütfi Kırdar City Hospital, Istanbul, Turkey.
Expert opinion on investigational drugs
|October 9, 2023
概括
新的Janus激酶抑制剂 (JAKis) 显示出对髓纤维化治疗的希望,提供改善的贫血和症状控制. 需要进一步的研究,以确定他们在个性化治疗中的全部潜力.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 简氏激酶抑制剂 (JAKis) 是骨髓纤维化症的标准治疗方法,改善了的大小和症状.
- 目前的JAKis提供好处,但面临诸如不容忍和不响应等挑战.
- 需要进一步的进展,以解决剩余的治疗障碍.
研究的目的:
- 审查JAK抑制剂治疗髓纤维化症的现状.
- 专注于研究中的JAKis,包括其临床前和临床试验结果.
- 讨论JAKis在个性化骨髓纤维化治疗中的潜力.
主要方法:
- 在 MEDLINE 和 clinicaltrials.gov 的文献搜索中,查找了骨髓纤维化中的 JAK 抑制剂研究.
- 包括已完成和正在进行的关于JAKIS的研究研究.
- 介绍和讨论每个药物的临床前和临床试验结果.
主要成果:
- 莫梅洛替尼在治疗骨髓纤维化患者的贫血方面表现出有效性.
- 雅克提尼布在改善贫血和总症状评分 (TSS) 方面表现出有效性.
- 几种新的JAKis正在调查中,结果呈现出不同的结果.
结论:
- 越来越多的JAK抑制剂可以为肌肉纤维化提供个性化治疗策略.
- 未来的评估应考虑疾病进展,分子反应和反应持续时间.
- 更多的第三阶段研究是必不可少的,以提供强有力的证据,为新的JAKis.
相关概念视频
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
180
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
180
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
181
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
181
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K


